

In Silico clinical trials for treatment of acute Ischemic Stroke

In Silico Models for thrombosis

and thrombolysis


Remy Petkantchin, Franck Raynaud, Bastien Chopard

University of Geneva, Switzerland.




September $25^{\rm th}$ 2019





















Source: https://www.blutwert.net










Source: https://www.blutwert.net



In Silico Models for thrombosis and thrombolysis, September 25^{th} 2019

Stroke






Source: https://www.webmd.com

- 1st cause of disability and 3rd cause of death in the West
- 1+ M Europeans have a first stroke/year
- 1/3 die, 1/3 permanently disabled
- ~ 2/3 of treated patients become functionally dependent
- ▶ \sim €27 billion/year in Europe
- Numbers rising due to population ageing

Source: https://insist-h2020.eu/

Stroke





Source: https://www.webmd.com

Treatment


- Injection of dissolving product (tPA): thrombolysis
- Mechanical removal of the clot: thrombectomy

- 1st cause of disability and 3rd cause of death in the West
- 1+ M Europeans have a first stroke/year
- 1/3 die, 1/3 permanently disabled
- ~ 2/3 of treated patients become functionally dependent
- ▶ \sim €27 billion/year in Europe
- Numbers rising due to population ageing

Source: https://insist-h2020.eu/

Thrombolysis Three months after therapy





Source: https://patient.info/doctor/thrombolytic-treatment-of-acute-ischaemic-stroke

In Silico Models for thrombosis and thrombolysis, September 25^{th} 2019





- European H2020 project, 9 universities + industrial partners.
- Main purpose: understand and predict thrombolysis and thrombectomy outcome for stroke patients.
- Method: generate virtual populations based on anonymous patients data, simulate treatment, and assess outcome.

Our part in the project







- Thrombolysis model: why is there such variability in outcome?
- Thrombosis model: how and when is the clot created?
- Coupled thrombosis/thrombolysis model: equilibrium between clot formation and dissolution?

Our part in the project









Thrombolysis model: why is there such variability in outcome?

- Thrombosis model: how and when is the clot created?
- Coupled thrombosis/thrombolysis model: equilibrium between clot formation and dissolution?

Thrombolysis









Thrombolysis






https://en.wikipedia.org/wiki/Fibrinolysis




M. Pantheleev's group Model with 6 equations (6 entities).

Fibrinolysis







M. Pantheleev's group Model with 6 equations (6 entities).


Inspired by: https://en.wikipedia.org/wiki/Fibrinolysis

Simplification

Reduction to 2 entities: **Fibrin** (F_n) and **tPA**.


2-species model






Artery model





Source: https://www.thingiverse.com/thing:1233389



Thrombolysis






$v_{seepage}$ vs porosity and length



---- Exponential fit


0.8

0.9



Clot heterogeneity






Source: S. De Meyer et al. (KUL)


Clot heterogeneity





Clot heterogeneity





Does it explain treatment outcome? Clot representation OK?



Takeaway

- Phenomenology not fully grasped.
- In silico trials to optimize treatment, patient-based.
- High societal stakes.

Thank you!